Japan's Global Health Initiative Technology Fund is investing $15.3 million to speed the development of new drugs and vaccines for malaria, dengue and Chagas disease. Japanese company Kaketsuken and Thailand's Mahidol University will share $3 million of that, which will go toward the development of a new dengue vaccine. Another $2 million will be shared between the Sabin Vaccine Institute, Baylor College of Medicine, Eisai and Aeras for a Chagas disease vaccine. Another notable portion of those funds, $3.8 million, will fund a malaria drug being designed by St. Jude Children's Research Hospital, Eisai and Switzerland's Medicines for Malaria Venture. Another $3 million was awarded to the Broad Institute and Eisai for a malaria therapy. More